Vertex Pharmaceuticals, Inc., a pharmaceutical company known for discovering, developing and commercializing novel medicines for serious diseases with largely unmet clinical needs such as cystic fibrosis (CF), recently revealed the company’s corporate outlook for the year 2015, prior to their scheduled presentation at the highly-anticipated 33rd J.P. Morgan Healthcare…
News
A new editorial entitled “Comparing cystic fibrosis outcomes across the pond” was recently published online in the journal Thorax. In the editorial, David C Taylor-Robinson from the Department of Public Health and Policy, at the University of Liverpool in the United Kingdom along with colleagues discuss…
Norwood, Massachusetts-based, Corbus Pharmaceuticals Holdings, Inc., recently announced their Chief Executive Officer, Yuval Cohen, Ph.D., has been invited to present at two upcoming investor conferences. Both presentations will highlight and discuss Corbus’ lead pipeline therapeutic for serious inflammatory and fibrotic conditions, Resunab™, which has as its active ingredient, ajulemic…
KaloBios Pharmaceuticals, Inc. recently announced data on a Phase 2 randomized double-blind, placebo-controlled trial of KB001-A, an anti-PcrV monoclonal antibody (mAb) fragment, to be used as treatment for Pseudomonas aeruginosa (Pa) lung infections in subjects with cystic fibrosis (CF). The KB001-A trial enrolled 182 patients with CF who had their lungs…
Protalix BioTherapeutics, Inc., an Israeli pharmaceutical company known for its proprietary, US Food and Drug Administration-approved, plant-based enzyme taliglucerase alfa for Gaucher disease, recently announced their new company strategy for accelerated growth. The Company has begun reinforcing their R&D efforts and laying new groundwork for a renewed focus on…
In a report published this week by SPIE — an international not-for-profit society serving more than 256,000 constituents from approximately 155 countries advancing an interdisciplinary approach to the science and application of light — entitled “Laser trapping to show the effects of bacterial arrangement on biofilm infection” (30 December 2014,…
As the year 2014 comes to a close, Cystic Fibrosis News Today — your reliable online source for the latest on cystic fibrosis treatments, events, clinical trials, and research updates — has outlined our “Top 14 Cystic Fibrosis Stories of 2014.” The following 14 stories were ranked according to the…
Vertex Pharmaceuticals has just announced the US Food and Drug Administration has granted their lead cystic fibrosis treatment Kalydeco® (ivacaftor) a supplemental new drug application (sNDA). Kalydeco was originally formulated to treat CF in patients aged 6 years and older who carry the…
The Committee for Medicinal Products for Human Use (CHMP) issued a positive recommendation for the commercialization of Quinsair (240 mg) as a therapeutic for adult patients with cystic fibrosis with recurrent infections by Pseudomonas aeruginosa. Cystic Fibrosis (CF) is an inherited disease that is characterized by defective mucus secretions…
A new study entitled “Microbiological diagnostic procedures for respiratory cystic fibrosis samples in Spain: towards standard of care practices” was published in BMC Microbiology by Juan de Dios Caballero and a group of researchers from Spain. In this study, the authors evaluated the compliance of microbiological procedures…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.